These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35269482)

  • 1. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss.
    Ho DH; Nam D; Seo M; Park SW; Seol W; Son I
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.
    Schapansky J; Nardozzi JD; LaVoie MJ
    Neuroscience; 2015 Aug; 302():74-88. PubMed ID: 25284317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.
    Maekawa T; Sasaoka T; Azuma S; Ichikawa T; Melrose HL; Farrer MJ; Obata F
    BMC Neurosci; 2016 Nov; 17(1):77. PubMed ID: 27903237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
    Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
    Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.
    Kim C; Beilina A; Smith N; Li Y; Kim M; Kumaran R; Kaganovich A; Mamais A; Adame A; Iba M; Kwon S; Lee WJ; Shin SJ; Rissman RA; You S; Lee SJ; Singleton AB; Cookson MR; Masliah E
    Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.
    Xu E; Boddu R; Abdelmotilib HA; Sokratian A; Kelly K; Liu Z; Bryant N; Chandra S; Carlisle SM; Lefkowitz EJ; Harms AS; Benveniste EN; Yacoubian TA; Volpicelli-Daley LA; Standaert DG; West AB
    Mol Neurodegener; 2022 Jan; 17(1):7. PubMed ID: 35012605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 regulates ferroptosis through the system Xc-GSH-GPX4 pathway in the neuroinflammatory mechanism of Parkinson's disease.
    Zheng Z; Zhang S; Liu X; Wang X; Xue C; Wu X; Zhang X; Xu X; Liu Z; Yao L; Lu G
    J Cell Physiol; 2024 May; 239(5):e31250. PubMed ID: 38477420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson's Disease.
    Wang Y; Zhang X; Chen F; Chen L; Wang J; Xie J
    J Inflamm Res; 2021; 14():2583-2586. PubMed ID: 34168481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia.
    Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y; Golde TE; Kelly JW; Sierks MR; Schork NJ; Karin M; Ambasudhan R; Lipton SA
    Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33833060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.
    Russo I; Kaganovich A; Ding J; Landeck N; Mamais A; Varanita T; Biosa A; Tessari I; Bubacco L; Greggio E; Cookson MR
    Neurobiol Dis; 2019 Sep; 129():67-78. PubMed ID: 31102768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
    Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
    J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
    Çınar E; Tel BC; Şahin G
    Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy.
    Hinkle JT; Patel J; Panicker N; Karuppagounder SS; Biswas D; Belingon B; Chen R; Brahmachari S; Pletnikova O; Troncoso JC; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2118819119. PubMed ID: 35394877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation.
    Feng L; Lo H; Hong Z; Zheng J; Yan Y; Ye Z; Chen X; Pan X
    Glia; 2023 Sep; 71(9):2266-2284. PubMed ID: 37300531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.
    Russo I; Berti G; Plotegher N; Bernardo G; Filograna R; Bubacco L; Greggio E
    J Neuroinflammation; 2015 Dec; 12():230. PubMed ID: 26646749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.